Denali Therapeutics Inc. (DNLI)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
DNLI Insider Trading Activity
DNLI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $10,397,037 | 32 | 100 |
Related Transactions
| Cook Jennifer E. | director | 0 | $0 | 1 | $31,682 | $-31,682 |
| SATO VICKI L | director | 0 | $0 | 8 | $418,793 | $-418,793 |
| Ho Carole | Chief Medical Officer | 0 | $0 | 5 | $911,712 | $-911,712 |
| Schuth Alexander O. | COFO and Secretary | 0 | $0 | 6 | $1.03M | $-1.03M |
| Watts Ryan J. | President and CEO | 0 | $0 | 4 | $1.91M | $-1.91M |
| Schenkein David P | director | 0 | $0 | 1 | $1.93M | $-1.93M |
| Krognes Steve E. | director | 0 | $0 | 7 | $4.16M | $-4.16M |
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Activity of Denali Therapeutics Inc.
Over the last 12 months, insiders at Denali Therapeutics Inc. have bought $0 and sold $10.4M worth of Denali Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Denali Therapeutics Inc. have bought $0 and sold $72.76M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 550,000 shares for transaction amount of $9.9M was made by BRATTON DOUGLAS K (10 percent owner) on 2017‑12‑12.
List of Insider Buy and Sell Transactions, Denali Therapeutics Inc.
| 2025-01-07 | Sale | Watts Ryan J. | President and CEO | 7,650 0.0052% | $20.81 | $159,197 | -2.80% | |
| 2025-01-07 | Sale | Schuth Alexander O. | COFO and Secretary | 2,907 0.002% | $20.81 | $60,495 | -2.80% | |
| 2025-01-07 | Sale | Ho Carole | Chief Medical Officer | 2,907 0.002% | $20.81 | $60,495 | -2.80% | |
| 2025-01-07 | Sale | Krognes Steve E. | director | 3,339 0.0023% | $20.81 | $69,485 | -2.80% | |
| 2025-01-06 | Sale | Watts Ryan J. | President and CEO | 29,266 0.0208% | $20.22 | $591,759 | +3.88% | |
| 2025-01-06 | Sale | Schuth Alexander O. | COFO and Secretary | 12,255 0.0087% | $20.22 | $247,796 | +3.88% | |
| 2025-01-06 | Sale | Ho Carole | Chief Medical Officer | 12,255 0.0087% | $20.22 | $247,796 | +3.88% | |
| 2025-01-02 | Sale | SATO VICKI L | director | 3,080 0.0021% | $20.91 | $64,403 | -1.20% | |
| 2024-12-31 | Sale | Krognes Steve E. | director | 30,000 0.0207% | $20.25 | $607,500 | +1.23% | |
| 2024-11-11 | Sale | Schenkein David P | director | 59,441 0.0421% | $32.51 | $1.93M | -32.01% | |
| 2024-11-07 | Sale | Schuth Alexander O. | COFO and Secretary | 15,558 0.0109% | $29.91 | $465,286 | -27.38% | |
| 2024-11-07 | Sale | SATO VICKI L | director | 1,020 0.0007% | $30.00 | $30,600 | -27.38% | |
| 2024-11-01 | Sale | SATO VICKI L | director | 3,080 0.0022% | $27.07 | $83,376 | -19.57% | |
| 2024-10-18 | Sale | Watts Ryan J. | President and CEO | 40,000 0.028% | $27.69 | $1.11M | -19.41% | |
| 2024-09-30 | Sale | Krognes Steve E. | director | 30,000 0.0208% | $29.03 | $870,900 | -20.34% | |
| 2024-09-13 | Sale | SATO VICKI L | director | 1,020 0.0007% | $30.00 | $30,600 | -24.21% | |
| 2024-09-03 | Sale | SATO VICKI L | director | 3,080 0.0021% | $25.00 | $77,007 | -6.13% | |
| 2024-08-21 | Sale | Schuth Alexander O. | COFO and Secretary | 2,547 0.0018% | $24.78 | $63,115 | -4.44% | |
| 2024-08-21 | Sale | Ho Carole | Chief Medical Officer | 20,005 0.0137% | $24.57 | $491,571 | -4.44% | |
| 2024-08-20 | Sale | Watts Ryan J. | President and CEO | 2,260 0.0016% | $23.79 | $53,765 | +1.01% |
Insider Historical Profitability
| Watts Ryan J. | President and CEO | 253071 0.1743% | $3.59M | 0 | 65 | |
| Schuth Alexander O. | COFO and Secretary | 244308 0.1682% | $3.47M | 0 | 69 | |
| Ho Carole | Chief Medical Officer | 175673 0.121% | $2.49M | 0 | 64 | |
| SATO VICKI L | director | 107976 0.0744% | $1.53M | 0 | 28 | |
| Krognes Steve E. | director | 25757 0.0177% | $365,749.40 | 0 | 24 | |
| Cook Jennifer E. | director | 20038 0.0138% | $284,539.60 | 0 | 1 | |
| Schenkein David P | director | 9220 0.0063% | $130,924.00 | 0 | 5 | |
| BRATTON DOUGLAS K | 10 percent owner | 9984836 6.8759% | $141.78M | 1 | 12 | <0.0001% |
| Tessier-Lavigne Marc | director | 1870356 1.288% | $26.56M | 0 | 17 |
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.11B | |
$1,376,668 | 53 | 18.46% | $2.3B | |
$11,583,737 | 45 | 49.75% | $1.81B | |
$224,319,161 | 41 | 27.46% | $2.26B | |
$150,253,463 | 26 | -52.83% | $1.92B | |
$1,801,511 | 23 | 18.58% | $1.89B | |
$154,554,190 | 14 | 29.60% | $1.77B | |
$92,580,864 | 14 | -1.28% | $2.23B | |
$75,296,816 | 12 | 37.23% | $1.96B | |
$128,232,675 | 11 | 134.40% | $1.76B | |
$137,013,690 | 11 | 26.62% | $1.91B | |
$1,248,715 | 10 | 5.66% | $2.42B | |
$32,575,266 | 8 | 37.03% | $2.11B | |
$25,073,947 | 7 | -5.99% | $1.91B | |
$103,599,972 | 2 | -36.81% | $2.36B | |
$10,000,009 | 1 | 100.92% | $1.81B | |
$49,999,992 | 1 | 50.02% | $2.34B | |
$7,600,000 | 1 | -4.05% | $2.07B | |
Denali Therapeutics Inc. (DNLI) | $9,900,000 | 1 | -7.19% | $2.06B |
DNLI Institutional Investors: Active Positions
| Increased Positions | 127 | +55.95% | 9M | +6.66% |
| Decreased Positions | 93 | -40.97% | 8M | -6.07% |
| New Positions | 44 | New | 2M | New |
| Sold Out Positions | 32 | Sold Out | 748,295 | Sold Out |
| Total Postitions | 261 | +14.98% | 130M | +0.6% |
DNLI Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $200,869.00 | 9.6% | 13.92M | +131,728 | +0.95% | 2024-12-31 |
| Baillie Gifford & Co | $177,690.00 | 8.49% | 12.31M | -1M | -7.73% | 2024-12-31 |
| Vanguard Group Inc | $173,466.00 | 8.29% | 12.02M | +843,996 | +7.55% | 2024-12-31 |
| Wellington Management Group Llp | $142,106.00 | 6.79% | 9.85M | -879,499 | -8.2% | 2024-12-31 |
| Fmr Llc | $115,725.00 | 5.53% | 8.02M | +188,368 | +2.4% | 2024-12-31 |
| Capital Research Global Investors | $79,036.00 | 3.78% | 5.48M | -2M | -30.75% | 2024-12-31 |
| Temasek Holdings (Private) Ltd | $77,285.00 | 3.69% | 5.36M | 0 | 0% | 2024-12-31 |
| State Street Corp | $65,584.00 | 3.13% | 4.54M | +292,962 | +6.89% | 2024-12-31 |
| Crestline Management, Lp | $62,204.00 | 2.97% | 4.31M | -150,000 | -3.36% | 2024-12-31 |
| Baker Bros. Advisors Lp | $53,848.00 | 2.57% | 3.73M | 0 | 0% | 2024-12-31 |